Inclusion Criteria:  Participants with lcSSc classified by the 2013 EULAR ACR criteria for limited cutaneous subset of SSc Participants with less than 7 years disease duration from first non-Raynaud's manifestation of SSc Participants aged 18 years or more (≥ 18 years) at screening visit If women of child bearing potential, the participant must have a negative pregnancy test at screening and baseline visits Negative viral screen for HIV, Hepatitis B and C Ability to provide full informed consent Registered with a GP practice in the UK Participants must be willing to attend for follow up visits (at site or remotely) and to comply with study-related procedures -  Exclusion Criteria:  Having already developed a complication of SSc that requires initiation of MMF or an alternative major immunosuppressive drug for SSc such as methotrexate, cyclophosphamide or azathioprine Treatment with methotrexate, cyclosporine A, azathioprine, mycophenolate mofetil (MMF), rapamycin, colchicine, D-penicillamine, within ≤ 4 weeks prior to the baseline visit date Contraindication to MMF (e.g. active infection that would preclude MMF in judgement of investigator), or previous intolerance of MMF Any clinical condition which the investigator considers would make the patient unsuitable for the trial Pregnancy (or planned pregnancy during trial participation) and/or breastfeeding Women of child bearing potential and male participants with a partner of child bearing potential not willing to use adequate contraception as described in section 6.3.1.4 for the duration of trial treatment and within the time points specified following last trial treatment.  Active chronic infection such as COVID-19, tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria.  Suitability for enrolment once the participant has recovered from infection will be based on Investigator judgment.  Infection history:  i. Hospitalisation for treatment of infection within ≤ 8 weeks of screening visit date  ii. Use of parenteral (IV or IM) antibiotics (antibacterials, antivirals, anti-fungals, or anti-parasitic agents) within ≤ 4 weeks of screening visit date  Receipt of a live-attenuated vaccine within ≤ 12 weeks of screening visit date Participants enrolled in any other interventional trial within ≤ 4 weeks of the screening visit date (co-enrolment in observational studies is acceptable) Current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within ≤ 52 weeks prior to screening visit date.  Any of the following laboratory results at screening visit:  Glomerular filtration rate (GFR) <60 ml/min/1.73m² Absolute neutrophil count (ANC) < 1.6 x 10^9/l ALT or AST > 2 x ULN Participants not willing or unable to attend on-site screening visit.